TY - JOUR
T1 - Evolution of Chlorhexidine Susceptibility and of the EfrEF Operon among Enterococcus faecalis from Diverse Environments, Clones, and Time Spans
AU - Pereira, Ana P.
AU - Antunes, Patrícia
AU - Willems, Rob
AU - Corander, Jukka
AU - Coque, Teresa M.
AU - Peixe, Luísa
AU - Freitas, Ana R.
AU - Novais, Carla
N1 - Funding Information:
This work was financed by national funds from Fundação para a Ciência e a Tecnologia (FCT), I.P., in the scope of projects UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences–UCIBIO and project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy–i4HB, by the AgriFood XXI I&D&I project (NORTE-01-0145-FEDER-000041) cofinanced by the European Regional Development Fund (ERDF) and through the Programa Operacional Regional do Norte 2014/2020. Ana Paula Pereira was supported by Ph.D. fellowship SFRH/BD/144401/2019 from FCT, cofinanced by European Social Fund through Norte Portugal Regional Operational Program (NORTE 2020), and Ana R. Freitas was supported by the Junior Research Position (CEECIND/ 02268/2017 – Individual Call to Scientific Employment Stimulus 2017) granted by FCT/MCTES through national funds. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. Patrícia Antunes, Teresa M. Coque, Luísa Peixe, Ana R. Freitas, and Carla Novaisa are active members of the European Congress of Clinical Microbiology & Infectious Diseases Study Group on Food- and Water-borne Infections. Ana Paula Pereira: methodology, software, formal analysis, investigation, writing – original draft, writing – review & editing. Patrícia Antunes: formal analysis, investigation, writing – review & editing, funding acquisition. Rob Willems: formal analysis, writing – review & editing; Jukka Corander: formal analysis, writing – review & editing; Teresa M. Coque: formal analysis, writing – review & editing. Luísa Peixe: supervision, funding acquisition, formal analysis, writing – review & editing. Ana R. Freitas: conceptualization, methodology, formal analysis, supervision, writing – review & editing, funding acquisition. Carla Novais: conceptualization, methodology, software, formal analysis, investigation, supervision, writing – original draft, writing – review & editing, funding acquisition, project administration. We declare no conflict of interest.
Funding Information:
This work was financed by national funds from Fundação para a Ciência e a Tecnologia (FCT), I.P., in the scope of projects UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences–UCIBIO and project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy–i4HB, by the AgriFood XXI I&D&I project (NORTE-01-0145-FEDER-000041) cofinanced by the European Regional Development Fund (ERDF) and through the Programa Operacional Regional do Norte 2014/2020. Ana Paula Pereira was supported by Ph.D. fellowship SFRH/BD/144401/2019 from FCT, cofinanced by European Social Fund through Norte Portugal Regional Operational Program (NORTE 2020), and Ana R. Freitas was supported by the Junior Research Position (CEECIND/ 02268/2017 – Individual Call to Scientific Employment Stimulus 2017) granted by FCT/MCTES through national funds.
Publisher Copyright:
© 2022 Pereira et al.
PY - 2022/8/31
Y1 - 2022/8/31
N2 - Chlorhexidine (CHX) is widely used to control the spread of pathogens (e.g., human/animal clinical settings, ambulatory care, food industry). Enterococcus faecalis, a major nosocomial pathogen, is broadly distributed in diverse hosts and environments facilitating its exposure to CHX over the years. Nevertheless, CHX activity against E. faecalis is understudied. Our goal was to assess CHX activity and the variability of ChlR-EfrEF proteins (associated with CHX tolerance) among 673 field isolates and 1,784 E. faecalis genomes from the PATRIC database from different sources, time spans, clonal lineages, and antibiotic-resistance profiles. The CHX MIC (MIC
CHX) and minimum bactericidal concentration (MBC
CHX) against E. faecalis presented normal distributions (0.5 to 64 mg/L). However, more CHX-tolerant isolates were detected in the food chain and recent human infections, suggesting an adaptability of E. faecalis populations in settings where CHX is heavily used. Heterogeneity in ChlR-EfrEF sequences was identified, with isolates harboring incomplete ChlR-EfrEF proteins, particularly the EfrE identified in the ST40 clonal lineage, showing low MIC
CHX (#1mg/L). Distinct ST40-E. faecalis subpopulations carrying truncated and nontruncated EfrE were detected, with the former being predominant in human isolates. This study provides a new insight about CHX susceptibility and ChlR-EfrEF variability within diverse E. faecalis populations. The MIC
CHX/MBC
CHX of more tolerant E. faecalis (MIC
CHX = 8 mg/L; MBC
CHX = 64 mg/L) remain lower than in-use concentrations of CHX ($500 mg/L). However, increased CHX use, combined with concentration gradients occurring in diverse environments, potentially selecting multidrug-resistant strains with different CHX susceptibilities, signals the importance of monitoring the trends of E. faecalis CHX tolerance within a One Health approach.
AB - Chlorhexidine (CHX) is widely used to control the spread of pathogens (e.g., human/animal clinical settings, ambulatory care, food industry). Enterococcus faecalis, a major nosocomial pathogen, is broadly distributed in diverse hosts and environments facilitating its exposure to CHX over the years. Nevertheless, CHX activity against E. faecalis is understudied. Our goal was to assess CHX activity and the variability of ChlR-EfrEF proteins (associated with CHX tolerance) among 673 field isolates and 1,784 E. faecalis genomes from the PATRIC database from different sources, time spans, clonal lineages, and antibiotic-resistance profiles. The CHX MIC (MIC
CHX) and minimum bactericidal concentration (MBC
CHX) against E. faecalis presented normal distributions (0.5 to 64 mg/L). However, more CHX-tolerant isolates were detected in the food chain and recent human infections, suggesting an adaptability of E. faecalis populations in settings where CHX is heavily used. Heterogeneity in ChlR-EfrEF sequences was identified, with isolates harboring incomplete ChlR-EfrEF proteins, particularly the EfrE identified in the ST40 clonal lineage, showing low MIC
CHX (#1mg/L). Distinct ST40-E. faecalis subpopulations carrying truncated and nontruncated EfrE were detected, with the former being predominant in human isolates. This study provides a new insight about CHX susceptibility and ChlR-EfrEF variability within diverse E. faecalis populations. The MIC
CHX/MBC
CHX of more tolerant E. faecalis (MIC
CHX = 8 mg/L; MBC
CHX = 64 mg/L) remain lower than in-use concentrations of CHX ($500 mg/L). However, increased CHX use, combined with concentration gradients occurring in diverse environments, potentially selecting multidrug-resistant strains with different CHX susceptibilities, signals the importance of monitoring the trends of E. faecalis CHX tolerance within a One Health approach.
KW - Bacillota (former Firmicutes)
KW - One Health
KW - biocide
KW - minimum bactericidal concentration
KW - minimum inhibitory concentration
UR - https://www.scopus.com/pages/publications/85137138912
U2 - 10.1128/spectrum.01176-22
DO - 10.1128/spectrum.01176-22
M3 - Article
C2 - 35862993
SN - 2165-0497
VL - 10
JO - Microbiology spectrum
JF - Microbiology spectrum
IS - 4
M1 - e0117622
ER -